(Meloxicam + esomeprazole) is under clinical development by Axsome Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect (Meloxicam + esomeprazole)’s likelihood of approval (LoA) and phase transition for Osteoarthritis took place on 20 Nov 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Meloxicam + esomeprazole) Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
(Meloxicam + esomeprazole) overview
AXS-06 is a fixed dose combination of (meloxicam + esomeprazole) is under development for the treatment of osteoarthritis, rheumatoid arthritis, chronic pain and NSAID associated gastric ulcers. It is administered through oral route. The drug candidate is a small molecule and developed based on Axsome’s MoSEIC delivery technology.
Axsome Therapeutics overview
Axsome Therapeutics (Axsome) is a biopharmaceutical company that develops and commercializes therapies for the treatment of central nervous system (CNS) disorders. The company’s pipeline product portfolio comprises AXS-05, for treatment of resistant depression, smoking cessation and agitation in Alzheimer’s disease, AXS-07, for treatment of migraine, AXS-12, for symptoms of narcolepsy, and AXS-14, for treatment of fibromyalgia. The company supplies its products through internal sales, distributors, and an internal marketing group in the US and outside the US. Axsome is headquartered in New York, the US.
Quick View (Meloxicam + esomeprazole) LOA Data
|Highest Development Stage|